Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Kirenol alleviates diabetic nephropathy via regulating TGF-β/Smads and the NF-κB signal pathway.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Taylor & Francis Country of Publication: England NLM ID: 9812552 Publication Model: Print Cited Medium: Internet ISSN: 1744-5116 (Electronic) Linking ISSN: 13880209 NLM ISO Abbreviation: Pharm Biol Subsets: MEDLINE
- Publication Information:
Publication: [London] : Taylor & Francis
Original Publication: Lisse, the Netherlands : Swets & Zeitlinger, c1998-
- Subject Terms:
- Abstract:
Context: Kirenol possesses anti-inflammatory, antifibrotic and anti-arthritic effects. However, its reno-protective effects against diabetic nephropathy (DN) have not been evaluated.
Objective: This study explores the reno-protective effects of kirenol against DN and clarifies the potential mechanisms.
Materials and Methods: The mesangial cells were treated with 20 µM kirenol and 10 ng/mL human recombinant TGF-β1 or 30 mM glucose for 24 h. Then the cells were harvested to assay the expression of the target genes or proteins. Thirty C57BL/6J male mice were given high-fat diet with streptozotocin injection to induce diabetes and then were randomized into three groups ( n = 10): vehicle administration (DM group), 2 mg/kg kirenol (DM + kirenol group) and 200 mg/kg metformin (Met group) for 3 months, orally. A healthy group (Con, n = 10) was included as the control.
Results: Compared to the DM group, kirenol treatment decreased the phosphorylation of Smad2/3 and NF-κB (0.64- and 0.43-fold) as well as the accumulation of FN and Col IV (0.58- and 0.35-fold); moreover, the expression of IκBα was restored to normal level by kirenol treatment both in vivo and in vitro . After kirenol treatment, IL-6 expression was decreased 0.35- and 0.57-fold, and TNF-α expression was decreased 0.34- and 0.46-fold, in vitro and in vivo , respectively. Furthermore, kirenol alleviated the glomerular basement membrane thickness and foot process fusion.
Discussion and Conclusions: Kirenol could alleviate DN by downregulating the TGF-β/Smads and the NF-κB signal pathway. Our study provides a potential mechanism for the treatment of DN with kirenol.
- References:
J Pharmacol Sci. 2020 Feb;142(2):41-49. (PMID: 31831259)
Front Pharmacol. 2019 Jul 30;10:715. (PMID: 31417401)
Kidney Int. 2021 Oct;100(4):809-823. (PMID: 34147551)
J Med Food. 2020 Dec;23(12):1275-1286. (PMID: 33090944)
J Biol Chem. 2014 Oct 17;289(42):28827-34. (PMID: 25164822)
Front Med (Lausanne). 2021 Dec 06;8:732042. (PMID: 34938743)
Eur J Pharmacol. 2013 Aug 5;713(1-3):6-15. (PMID: 23665496)
Inflamm Res. 2020 Dec;69(12):1215-1234. (PMID: 33044562)
Int J Biochem Cell Biol. 2012 Apr;44(4):629-38. (PMID: 22245600)
Drug Des Devel Ther. 2020 Oct 08;14:4135-4148. (PMID: 33116403)
Fitoterapia. 2014 Oct;98:59-65. (PMID: 25062891)
J Ethnopharmacol. 2021 Mar 25;268:113547. (PMID: 33152433)
Am J Physiol Renal Physiol. 2016 Apr 1;310(7):F596-F606. (PMID: 26739888)
Kidney Int. 2003 Jun;63(6):2010-9. (PMID: 12753288)
Biomed Pharmacother. 2018 Oct;106:1250-1257. (PMID: 30119194)
J Clin Med. 2020 Feb 07;9(2):. (PMID: 32046074)
Front Endocrinol (Lausanne). 2018 Jun 07;9:275. (PMID: 29930535)
J Diabetes Res. 2018 Jun 27;2018:1031367. (PMID: 30050950)
Nat Rev Nephrol. 2016 Jun;12(6):325-38. (PMID: 27108839)
J Cell Physiol. 2020 Apr;235(4):3362-3371. (PMID: 31549412)
J Ethnopharmacol. 2021 Jan 30;265:113294. (PMID: 32841693)
J Physiol Pharmacol. 2021 Feb;72(1):. (PMID: 34099583)
Diabetes Care. 2009 Sep;32(9):1684-8. (PMID: 19502542)
J Ethnopharmacol. 2011 Oct 11;137(3):1089-94. (PMID: 21798328)
Nat Rev Endocrinol. 2016 Oct;12(10):566-92. (PMID: 27339889)
Eur Cardiol. 2019 Apr;14(1):50-59. (PMID: 31131037)
Int J Clin Pharmacol Ther. 2012 Nov;50(11):805-13. (PMID: 22943927)
Kidney Int. 2011 May;79(10):1042-4. (PMID: 21527942)
J Ethnopharmacol. 2021 Dec 5;281:114552. (PMID: 34438028)
Biomolecules. 2021 Oct 07;11(10):. (PMID: 34680110)
Chin Med. 2019 Sep 23;14:35. (PMID: 31572487)
Adv Exp Med Biol. 2019;1165:49-79. (PMID: 31399961)
Evid Based Complement Alternat Med. 2017;2017:7187038. (PMID: 28638433)
Annu Rev Pathol. 2011;6:395-423. (PMID: 21261520)
FASEB J. 2020 Feb;34(2):2554-2567. (PMID: 31909536)
Pharmacol Res. 2020 Feb;152:104630. (PMID: 31911245)
Phytomedicine. 2021 Jan;80:153377. (PMID: 33126167)
Signal Transduct Target Ther. 2020 Sep 21;5(1):209. (PMID: 32958760)
J Cell Mol Med. 2019 Nov;23(11):7651-7663. (PMID: 31565849)
J Endocrinol. 2018 Jul;238(1):47-60. (PMID: 29720537)
Diabetes. 2001 Oct;50(10):2376-83. (PMID: 11574422)
Kidney Int. 2018 Jan;93(1):95-109. (PMID: 28750927)
Biomed Pharmacother. 2020 Sep;129:110475. (PMID: 32768960)
Acta Pharmacol Sin. 2015 Jul;36(7):831-40. (PMID: 25937636)
Biochem Biophys Res Commun. 2016 May 13;473(4):931-938. (PMID: 27055593)
- Contributed Indexing:
Keywords: IL-6; TNF-α; collagen IV; fibronectin; mesangial cells
- Accession Number:
0 (Diterpenes)
0 (NF-kappa B)
0 (Transforming Growth Factor beta)
0 (Transforming Growth Factor beta1)
0 (kirenol)
- Publication Date:
Date Created: 20220908 Date Completed: 20220912 Latest Revision: 20220914
- Publication Date:
20231215
- Accession Number:
PMC9467559
- Accession Number:
10.1080/13880209.2022.2112239
- Accession Number:
36073930
No Comments.